How Accurate Is Gender Selection in Georgia IVF? PGT Technology Principles and Clinical Data Interpretation

Doctor's Decision Logic: Why Patients Care About Gender Selection Accuracy

In the consultation room of a Georgian reproductive center, a doctor faces a couple. The husband carries a gene for an X-linked recessive genetic disease, and they need to select a female embryo to prevent the offspring from being affected. Another family, having already raised two sons, hopes to achieve family balance through gender selection. When formulating a PGT-A plan, the doctor is repeatedly asked the same question: "How accurate is gender selection? Could it be wrong?"

Behind this question lies the patient's core concern of equating "gender selection accuracy" with "whether the technology is reliable." From a reproductive medicine perspective, this question cannot be simply answered with "99%" or "100%." It requires breaking down the technical principles, biological limitations, and clinical statistical definitions.

Direct Answer to the Question: Accuracy Range of PGT-A Gender Determination

PGT-A technology based on next-generation sequencing (NGS) platforms screens embryos for aneuploidy across all 23 pairs of chromosomes while simultaneously determining the sex chromosome composition (XX or XY). For embryos that pass quality control, the technical accuracy of gender determination exceeds 99%. However, this data needs to be understood on the following three levels:

• Technical Detection Accuracy: Refers to the consistency of repeated test results on the same biopsied cell sample within the laboratory, typically >99.5%.
• Clinical Predictive Accuracy: Refers to the consistency between the test result and the actual sex of the newborn. Literature reports it to be between 98% and 99.4% (European Society of Human Reproduction and Embryology 2022 data).
• Patient's "Probability of Successfully Obtaining an Embryo of the Desired Sex": This depends on how many euploid embryos the patient has available for selection and is a different concept from accuracy.

Therefore, to directly answer "Is the accuracy high?" — based on the technology itself, it is very high. However, equating "accuracy" with "definitely giving birth to a child of the selected sex" represents a misunderstanding.

Deep Reasons Why This Question Arises

Patients' anxiety about "gender selection accuracy" stems from the following three facts:

• Current technology cannot 100% rule out mosaicism: Embryos may develop with inconsistent chromosomal compositions in different cells (mosaicism) during early development. If the biopsied trophectoderm cells are XX, but the inner cell mass is XY (or vice versa), the test result may not match the actual sex of the fetus. The incidence of mosaicism varies by age and embryo grade, approximately 2%-5%.
• False positives/negatives due to technical limitations: Although NGS technology has greatly reduced error rates, factors such as sample contamination, DNA amplification bias, and minor chromosomal structural abnormalities can still lead to a very low probability of misdiagnosis.
• Patients confuse "gender selection" with "embryo selection": The primary goal of PGT-A is to screen for euploid embryos (normal chromosome number); gender determination is a "byproduct." Patients often focus solely on gender, neglecting that the health of the embryo itself is the key factor determining transplant success.

Differences Across Age Groups: Age Does Not Affect Gender Determination Accuracy, But Affects the Number of Transferable Embryos

From an embryology laboratory perspective, the detection accuracy of PGT-A for sex chromosomes is not affected by the patient's age. Whether the patient is 25 or 42 years old, as long as the biopsy sample quality meets standards, the accuracy of XX/XY determination on the NGS platform is consistent.

However, age affects the "probability of ultimately obtaining an embryo of the desired sex" through the following pathways:

• Decreased euploidy rate: The proportion of euploid blastocysts in women under 35 is about 50%-60%, dropping to 20%-30% in women over 40. If a 38-year-old patient obtains 5 blastocysts, only 1-2 may be chromosomally normal. If these euploid embryos are not of the desired sex, gender selection cannot be achieved.
• Reduced number of biopsiable embryos: Advanced age leads to fewer eggs retrieved, resulting in a lower number of blastocysts formed and a smaller base of embryos available for PGT-A.

Easily Overlooked Detail: Representativeness of Biopsied Cells vs. Embryonic Reality

In the clinical practice of Georgian reproductive centers, embryologists repeatedly emphasize a core concept: PGT-A tests trophectoderm cells, not the inner cell mass. Trophectoderm cells will develop into the placenta, while the inner cell mass develops into the fetus. Although they are homologous, in rare cases, their chromosomal composition may differ (mosaicism).

This means: if the test result indicates a male embryo (XY), the probability of it developing into a female infant after transfer is extremely low (<0.5%), but it cannot be completely ruled out medically. This is information that any legitimate reproductive center must disclose in the informed consent form.

Common Pitfall: Confusing Technical Accuracy with Clinical Success Rate

From the perspective of overseas coordinators and patient education specialists, the most frequently observed cognitive misconceptions include:

• Misconception 1: "PGT-A is 99% accurate, so if I choose a male embryo, I will definitely give birth to a boy." In reality, accurate sex determination does not equate to successful embryo implantation and live birth. Issues such as implantation failure, early miscarriage, and mid-to-late pregnancy loss can still occur and are unrelated to gender selection accuracy.
• Misconception 2: "The sex of a mosaic embryo is definitely inaccurate." The impact of mosaicism on gender determination varies with the proportion of mosaicism. For embryos with low-level mosaicism (<20%), the mainstream reproductive medicine view is that they can be transferred, with the sex determined by the predominant cell line, but prenatal diagnosis is recommended.
• Misconception 3: "I can transfer an aneuploid embryo just to select the sex." Some clinics may encourage the transfer of embryos with sex chromosome abnormalities (e.g., 47,XXY). This practice raises serious medical ethical concerns and typically results in poor pregnancy outcomes.

Special Case Management: Gender Determination for Embryos with Sex Chromosome Abnormalities

In PGT-A testing, if an embryo shows an abnormal number of sex chromosomes (e.g., XO, XXY, XYY), gender determination requires combined clinical genetic counseling:

• 45,X (Turner Syndrome): Phenotype is female, but with issues like growth retardation and ovarian dysgenesis. Whether to transfer requires assessment of genetic risk and patient preference.
• 47,XXY (Klinefelter Syndrome): Phenotype is male, but with issues like hypogonadism and infertility. It is generally not considered a suitable embryo for transfer in reproductive centers.
• 47,XYY: Phenotype is male, with most patients being asymptomatic or having only mild behavioral characteristics. Transfer is allowed in some countries but requires full disclosure.

In Georgia, the disposition of embryos with sex chromosome abnormalities follows local laws and ethics committee guidelines, generally recommending against transfer or use for research.

Frequently Asked Questions and Clarification of Misconceptions

Q1: Why is the sex of the embryo I selected different from the final result?

Possible reasons include: undetected embryo mosaicism, biopsy sample contamination, laboratory interpretation error (very low probability), or the patient selecting a different sex embryo during transfer. It is recommended to reconfirm the embryo information with the embryologist before transfer.

Q2: Can mosaic embryos be transferred? Is the sex accurate?

Mosaic embryos can be transferred under specific conditions, but the sex is primarily based on the test result. After transfer, prenatal confirmation via non-invasive prenatal testing (NIPT) or amniocentesis is recommended. NIPT has high accuracy for sex chromosome determination, but the final confirmation relies on amniocentesis karyotype analysis.

Q3: What are the specific regulations of Georgian law regarding gender selection?

Georgia allows embryo gender selection for medical indications (such as sex-linked genetic diseases, severe sex-limited diseases). For non-medical "family balancing" needs, the law does not explicitly prohibit it, but reproductive centers typically require patients to provide a written declaration and undergo ethical review. Specific implementation depends on the policy of the patient's chosen reproductive center.

Medical Practice and Legal Framework in Georgia

In several major reproductive centers in Tbilisi, Georgia, gender selection is achieved through the following process:

• Medical Indication Verification: The doctor assesses the risk of sex-related genetic diseases, such as hemophilia, Duchenne muscular dystrophy, and X-linked intellectual disability.
• Non-Medical Need Assessment: Some centers accept requests for family balancing but require patients to sign an informed consent form acknowledging the accuracy rates and risks.
• Unified Use of NGS Platform for PGT-A Testing: Testing includes aneuploidy screening for all 23 pairs of chromosomes and reports the sex chromosome composition.
• Pre-Transfer Embryo Confirmation: On the day of transfer, the embryologist, doctor, and patient confirm the embryo number and sex report together.

From a legal perspective, Georgia's assisted reproduction law imposes different restrictions on gender selection depending on the situation. Patients should not assume that all centers accept any form of gender selection and must confirm directly during consultation.

Risk Reminder: PGT-A Is Not a "Perfect Baby" Tool

As a reproductive medicine editor, it must be reiterated: PGT-A is a screening technology, not a diagnostic technology. It cannot detect all minor chromosomal variations (such as microdeletions, microduplications) nor rule out single-gene disorders. Gender selection is just one of its functions. Making gender selection the primary goal of IVF may deviate from the medical essence.

For those considering gender selection in Georgia, it is recommended to complete the following before departure:

• Clarify your actual medical need: Is it to avoid genetic diseases or solely for family balancing?
• Consult a genetic doctor: If there is a family history of genetic disease, confirm whether it can be effectively prevented through gender selection.
• Understand the specific policies of the center: Different centers have varying degrees of openness towards non-medical gender selection.
• Be prepared to accept prenatal diagnosis: Even if the PGT-A result is clear, amniocentesis or NIPT verification is still recommended after pregnancy.

In any case, gender selection accuracy does not equal reproductive success. Establishing reasonable expectations is the most important step in the overseas assisted reproduction process.